Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: Role in renoprotection in obese rats

Hypertension

Volumn 61, Issue 6, 2013, Pages 1218-1226

  Dhande, Isha ^a,b   Ali, Quaisar ^a,b   Hussain, Tahir ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

anti inflammatory; AT2 Receptor; C21; interleukin 10; nitric oxide; renoprotection

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; C 21; CD68 ANTIGEN; HORMONE RECEPTOR STIMULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EPITHELIUM; MACROPHAGE; MALE; MORPHOMETRICS; NONHUMAN; OBESITY; PREHYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING;

ANTI-INFLAMMATORY; AT2 RECEPTOR; C21; INTERLEUKIN-10; NITRIC OXIDE; RENOPROTECTION;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; INTERLEUKIN-10; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; OBESITY; RATS; RATS, ZUCKER; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 84878924898     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00422     Document Type: Article

References (44)

1. Girndt M, Köhler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Büschenfelde KH, Fleischer B. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 1995; 47: 559-565.
2. Hunter CA, Ellis-Neyes LA, Slifer T, Kanaly S, Grünig G, Fort M, Rennick D, Araujo FG. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol. 1997; 158: 3311-3316. (Pubitemid 127484048)
3. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, Li L. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006; 147: 44-50. (Pubitemid 43004261)
4. Hakam AC, Hussain T. Renal angiotensin AT2 receptors are upregulated and mediate the candesartan induced natriuresis/dieresis in obese rats. Hypertension. 2005; 45: 270-275. (Pubitemid 40179971)
5. Tallam LS, Jandhyala BS. Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin-converting enzyme inhibition in obese Zucker rats. Clin Exp Pharmacol Physiol. 2001; 28: 433-440. (Pubitemid 32538911)
6. Sanchez-Lemus E, Murakami Y, Larrayoz-Roldan IM, Moughamian AJ, Pavel J, Nishioku T, Saavedra JM. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology. 2008; 149: 5177-5188.
7. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int. 2000; 58: 144-152. (Pubitemid 30429859)
8. Lin L, Phillips WE, Manning RD. Intrarenal Angiotensin ii is associated with inflammation, renal damage and dysfunction in dahl salt-sensitive hypertension. J Am Soc Hypertens. 2009; 3: 306-314.
9. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997; 95: 1532-1541. (Pubitemid 27142812)
10. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun. 1996; 226: 862-868. (Pubitemid 26348560)
11. Menè P, Fais S, Cinotti GA, Pugliese F, Luttmann W, Thierauch KH. Regulation of U-937 monocyte adhesion to cultured human mesangial cells by cytokines and vasoactive agents. Nephrol Dial Transplant. 1995; 10: 481-489.
12. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S. Contributions of angiotensin II and tumor-necrosis factor-? to the development of renal fibrosis. Am J Physiol Renal. 2001; 280: F777-F785.
13. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997; 100: 264-269. (Pubitemid 27349072)
14. Carey RM, Jin X, Wang Z, Siragy HM. Nitric oxide: A physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand. 2000; 168: 65-71. (Pubitemid 30128669)
15. Hakam AC, Hussain T. Angiotensin II AT2 receptors inhibit proximal tubular Na+K+ATPase activity via a NO/cGMP mediated pathway. Am J Renal Physiol. 2006; 290: F1430-F1436. (Pubitemid 43830769)
16. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J. 1997; 325 (pt 2): 449-454. (Pubitemid 27338727)
17. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem. 1997; 272: 19022-19026. (Pubitemid 27318258)
18. Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011; 57: 308-313.
19. Sabuhi R, Ali Q, Asghar M, Al-Zamily NRH, Hussain T. Role of angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese rats. Am J Renal Physiol. 2011; 300: F700-F706.
20. Curato C, Slavic S, Dong J, Skorska A, Altarche-Xifró W, Miteva K, Kaschina E, Thiel A, Imboden H, Wang J, Steckelings U, Steinhoff G, Unger T, Li J. Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. J Immunol. 2010; 185: 6286-6293.
21. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 1984; 26: 137-143. (Pubitemid 14017051)
22. Wang F, Xia ZF, Chen XL, Jia YT, Wang YJ, Ma B. Angiotensin II type-1 receptor antagonist attenuates LPS-induced acute lung injury. Cytokine. 2009: 48246-253.
23. Miyoshi M, Miyano K, Moriyama N, Taniguchi M, Watanabe T. Angiotensin type 1 receptor antagonist inhibits lipopolysaccharideinduced stimulation of rat microglial cells by suppressing nuclear factor kappaB and activator protein-1 activation. Eur J Neurosci. 2008; 27: 343-351.
24. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem. 1985; 54: 631-664. (Pubitemid 15073660)
25. Lavaud S, Michel O, Sassy-Prigent C, Heudes D, Bazin R, Bariéty J, Chevalier J. Early influx of glomerular macrophages precedes glomerulosclerosis in the obese Zucker rat model. J Am Soc Nephrol. 1996; 7: 2604-2615. (Pubitemid 27469567)
26. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant. 1998; 13: 1967-1974. (Pubitemid 28356760)
27. Wang Y, Tay YC, Harris DC. Proximal tubule cells stimulated by lipopolysaccharide inhibit macrophage activation. Kidney Int. 2004; 66: 655-662. (Pubitemid 38982008)
28. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997; 30: 1238-1246. (Pubitemid 27476185)
29. Ali Q, Sabuhi R, Hussain T. High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells. Mol Cell Biochem. 2010; 344: 65-71.
30. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts as anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor ?B. Hypertension. 2010; 55: 924-931.
31. Abadir PM, Walston JD, Carey RM, Siragy HM. Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNF? production. J Interferon Cytokine Res. 2011; 31: 471-474.
32. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-kappa B activity underlies the proand anti-inflammatory actions of nitric oxide. J Immunol. 2001; 166: 3873-3881. (Pubitemid 32224913)
33. Peng H, Libby P, Liao JK. Induction and stabilization of I?B? by nitric oxide mediates inhibition of NF?B. J Biol Chem. 1995; 270: 14214-14219.
34. Li Z, Zhang G, Feil R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of platelet integrin ?IIb?3. Blood. 2006; 107: 965-972. (Pubitemid 43156293)
35. Iliescu R, Chade AR. Progressive renal vascular proliferation and injury in obese Zucker rats. Microcirculation. 2010; 17: 250-258.
36. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a model of obesity and hypertension. Hypertension. 1989; 13: 896-901. (Pubitemid 19157987)
37. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988; 33: 667-672. (Pubitemid 18083115)
38. Viswanathan M, de Oliveira AM, Wu RM, Chiueh CC, Saavedra JM. [125I]CGP 42112 reveals a non-angiotensin II binding site in 1-methyl-4-phenylpyridine (MPP+)-induced brain injury. Cell Mol Neurobiol. 1994; 14: 99-104. (Pubitemid 24197984)
39. Macari D, Whitebread S, Cumin F, De Gasparo M, Levens N. Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol. 1994; 259: 27-36. (Pubitemid 24193189)
40. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000; 57: 167-182. (Pubitemid 30227764)
41. Manigrasso MR, Ferroni P, Santilli F, Taraborelli T, Guagnano MT, Michetti N, Davì G. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab. 2005; 90: 5876-5879. (Pubitemid 41415505)
42. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, Giugliano D. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003; 88: 1055-1058. (Pubitemid 36337756)
43. Siddiqui AH, Ali Q, Hussain T. Protective role of angiotensin II subtype 2 receptor in blood pressure increase in obese Zucker rats. Hypertension. 2009; 53: 256-261.
44. Yang J, Chen C, Ren H, Han Y, He D, Zhou L, Hopfer U, Jose PA, Zeng C. Angiotensin AT2 receptor decreases AT1 receptor expression and function via NO/cGMP/Sp1in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens. 2012; 30: 1176-1184.